High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
about
Malignant gliomas: old and new systemic treatment approachesDo relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysisEstimating dose painting effects in radiotherapy: a mathematical modelInter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair researchRadioactive (125)I seeds inhibit cell growth and epithelial-mesenchymal transition in human glioblastoma multiforme via a ROS-mediated signaling pathwayNRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cellsThe role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: A systematic review.Therapeutic strategies to improve drug delivery across the blood-brain barrier.Incidentalomas to glioblastoma multiforme.Impacts of MR spectroscopic imaging on glioma patient management.Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testingSurgical management of high-grade glioma: a standard of care.Prognostic significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, four new markers in high-grade gliomas.MGMT-Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of IDH Status and Chromosome 10q Deletion.MicroRNA-548c-3p inhibits T98G glioma cell proliferation and migration by downregulating c-MybTreatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured PopulationChildhood brain tumours due to germline bi-allelic mismatch repair gene mutations.Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era.Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium.Investigation of adhesion and mechanical properties of human glioma cells by single cell force spectroscopy and atomic force microscopy.Distinct genomic aberrations between low-grade and high-grade gliomas of Chinese patients.The prognostic role of preoperative serum albumin levels in glioblastoma patients.Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience.A pilot cost-effectiveness analysis of treatments in newly diagnosed high-grade gliomas: the example of 5-aminolevulinic Acid compared with white-light surgeryInternational Differences in Treatment and Clinical Outcomes for High Grade GliomaGenotoxic Damage to Glioblastoma Cells Treated with 6 MV X-Radiation in The Presence or Absence of Methoxy Estradiol, IUDR or Topotecan.Ion channel gene expression predicts survival in glioma patients.Girdin regulates the migration and invasion of glioma cells via the PI3K-Akt signaling pathway.Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypesLongitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 teslaEarly Detection of Malignant Transformation in Resected WHO II Low-Grade Glioma Using Diffusion Tensor-Derived Quantitative Measures.3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors.CELF1 is Up-Regulated in Glioma and Promotes Glioma Cell Proliferation by Suppression of CDKN1BThe vacuolar H+ ATPase is a novel therapeutic target for glioblastoma.Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling PathwayCD147 and glioma: a meta-analysis.From patient-specific mathematical neuro-oncology to precision medicineDARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy.
P2860
Q26744387-A6D89D5A-B858-490C-BFAB-78C8109658A5Q26865791-CD1C80C3-D62C-4FD1-B70F-390957AE4C56Q27321048-01C43B6F-8290-4539-B4AB-A83F9A2EFB4CQ28388726-E9B671EB-DC8C-404D-966D-F7AB15411114Q28393939-900D545E-1071-4E33-9481-9F9B45B3CC0FQ29247923-2A59F3BD-C842-4E2A-BDD2-E5FB5E3DBA64Q30250298-C18A490B-2CB1-46E7-955E-0B50AA0C7F9FQ30407443-F247C3A2-A818-400C-806F-46764FCD879EQ30411830-9CAA856A-2602-4ABD-BA3B-BFF61531E891Q30777660-B90244E4-83C6-4B29-9BE7-58D04332525DQ30810936-AD6D170E-931F-40E9-A75B-1C8D0DC4DABAQ30838365-145F0A03-D509-4612-BFED-C586B93DF12AQ31138637-2738DAF1-5FE8-4808-9ABC-80D53AAA0CABQ33615176-BD48A8F2-E2CC-41CB-A200-682C19A38190Q33684330-2A70FDC4-4110-43BE-BD5B-E34EB80BAD48Q33805484-6FFB31B2-17AA-4ED9-9CD4-CEC60EE7041AQ34160516-FF9CF3BB-6F12-49FF-9F23-B936FFFCD2FEQ34221722-6FF2C81D-D614-4B8F-BCA4-ACFE35E7C5F6Q34348199-9B7DC177-E05E-4154-983E-842C30E9FE04Q34497830-A1CAACF6-23DC-489B-8140-C784786232B5Q34603177-5D104AFE-92F4-4EFC-95E4-4A033281E6E0Q35164608-D40373DC-02E2-4086-83B5-F5A42129B0F2Q35184830-468CA0A4-3EE6-43B0-8078-E206DB1FC869Q35542158-155AD6F0-EFF3-4560-9161-B9C33DF4B0FEQ35659472-C1EEF312-2864-46A6-9457-DFFC01A18019Q35856038-0CB432EB-D091-4695-B36B-6BA003FE5914Q35909791-E71AD200-BE60-495C-ACB2-2235EA953D60Q36089868-7CB3459A-3283-46AA-812F-3D804D46399FQ36111611-BB373D1D-1164-4593-845F-21C435E08A2BQ36127425-FE39AF88-08CD-4277-8FC0-03BA54319082Q36164058-1196C8FF-FBAE-413E-8039-9A36856895A7Q36177805-C06D73B1-2689-4877-B31E-7EA32FF9C52AQ36222881-F0FDAD01-0ED1-4C7C-8E72-E30C100817ADQ36232092-5027315D-ACE9-4982-9621-4DCC9E79DE53Q36241711-26995B5C-61E9-4641-916A-7B5201BD50D5Q36247757-65CD9E6A-0EA7-476F-9D50-2BDDA4F381F1Q36385821-FD92C7A1-1D07-4D4F-8655-DCC3A7267C07Q36733380-F000A17D-342E-4208-90D9-680713B24FECQ36755933-9FAAE40E-1E2F-4029-9366-41FB393AAA08Q37187292-DA366230-1303-41BE-91AE-939E99B6E55C
P2860
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
High-grade malignant glioma: E ...... osis, treatment and follow-up.
@ast
High-grade malignant glioma: E ...... osis, treatment and follow-up.
@en
High-grade malignant glioma: E ...... osis, treatment and follow-up.
@nl
type
label
High-grade malignant glioma: E ...... osis, treatment and follow-up.
@ast
High-grade malignant glioma: E ...... osis, treatment and follow-up.
@en
High-grade malignant glioma: E ...... osis, treatment and follow-up.
@nl
prefLabel
High-grade malignant glioma: E ...... osis, treatment and follow-up.
@ast
High-grade malignant glioma: E ...... osis, treatment and follow-up.
@en
High-grade malignant glioma: E ...... osis, treatment and follow-up.
@nl
P2093
P2860
P356
P1433
P1476
High-grade malignant glioma: E ...... osis, treatment and follow-up.
@en
P2093
ESMO Guidelines Working Group
G Pentheroudakis
P2860
P304
P356
10.1093/ANNONC/MDQ187
P478
21 Suppl 5
P577
2010-05-01T00:00:00Z